Edwin Recreation area, a senior fellow on health policy at the Center on Policy and Budget Priorities, said that with the future of SCHIP uncertain after financing expires in March 2009, some states may decide to forgo expansion and even more modest changes like making enrollment less complicated when planning their budgets . This content is certainly republished with kind permission from our close friends at The Kaiser Family Foundation. You will see the complete Kaiser Daily Health Policy Report, search the archives, or join email delivery of in-depth coverage of health policy developments, discussions and debates.Vaccines for additional flaviviruses, such as yellow fever, Japanese encephalitis, and tickborne encephalitis, have already been successful. Industrial vaccine developers are working on bringing to market a tetravalent dengue vaccine that would protect both travelers to dengue endemic areas and the ones who live there. Some vaccines are in stage 2 clinical trials already; others are simply now moving to scientific trial. Furthermore to these good examples, Vaccines: Preventing Disease and Protecting Health provides in-depth discussions on the historical function of vaccines in disease avoidance and eradication; on the regulation and licensing of vaccines and the ethical and financial sustainability of vaccination programs; and on cutting-edge vaccine development ventures.